Enanta Pharmaceuticals' (ENTA) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Enanta Pharmaceuticals has had its "sell (D-)" rating reaffirmed by Weiss Ratings, indicating ongoing concerns among analysts about the company's stock performance.
• Despite the negative rating from Weiss, other brokerages have varied perspectives, with Wall Street Zen upgrading the stock to a "hold" and JMP Securities issuing a "market outperform" rating.
• Enanta reported a quarterly earnings surprise, posting a loss of ($0.85) per share, which was better than the consensus estimate of ($1.25), alongside revenue of $18.31 million exceeding expectations.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Several other brokerages also recently commented on ENTA. Wall Street Zen raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday, June 22nd. JMP Securities boosted their target price on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a "market outperform" rating in a report on Tuesday, August 12th. HC Wainwright began coverage on Enanta Pharmaceuticals in a report on Monday, July 28th. They issued a "buy" rating and a $20.00 target price on the stock. Evercore ISI reduced their target price on Enanta Pharmaceuticals from $20.00 to $12.00 and set an "outperform" rating on the stock in a report on Monday, September 15th. Finally, Westpark Capital boosted their target price on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a "buy" rating in a report on Tuesday, September 30th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.83.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA traded up $0.22 during trading on Wednesday, reaching $11.30. 584,438 shares of the company traded hands, compared to its average volume of 1,517,811. The stock's 50 day moving average price is $8.56 and its two-hundred day moving average price is $7.09. The company has a market cap of $241.59 million, a price-to-earnings ratio of -2.62 and a beta of 0.89. Enanta Pharmaceuticals has a 1-year low of $4.09 and a 1-year high of $15.34.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts' consensus estimates of ($1.25) by $0.40. The company had revenue of $18.31 million for the quarter, compared to the consensus estimate of $16.21 million. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%. Equities research analysts expect that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Millennium Management LLC raised its position in shares of Enanta Pharmaceuticals by 50.2% during the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company's stock valued at $7,435,000 after acquiring an additional 449,945 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Enanta Pharmaceuticals by 674.7% during the 1st quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company's stock valued at $1,971,000 after acquiring an additional 311,010 shares during the last quarter. Stonepine Capital Management LLC raised its position in shares of Enanta Pharmaceuticals by 78.0% during the 1st quarter. Stonepine Capital Management LLC now owns 590,742 shares of the biotechnology company's stock valued at $3,261,000 after acquiring an additional 258,842 shares during the last quarter. Trexquant Investment LP raised its position in shares of Enanta Pharmaceuticals by 113.4% during the 1st quarter. Trexquant Investment LP now owns 290,059 shares of the biotechnology company's stock valued at $1,601,000 after acquiring an additional 154,105 shares during the last quarter. Finally, PDT Partners LLC raised its position in shares of Enanta Pharmaceuticals by 217.5% during the 1st quarter. PDT Partners LLC now owns 106,200 shares of the biotechnology company's stock valued at $586,000 after acquiring an additional 72,751 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company's stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.